BCL2L1 and leukemia: On the other hand, the involvement of AKT-Bcl-xL axis in venetoclax resistance in leukemia was reported before (31, 32), and AKT pathway inhibition may facilitate the suppression of BCL2L1 in KG-1-FOXM1-KD cells.